In a study of 69 patients with KRAS exon 2 mutant CRC, IGF-1 expression was higher in rectal than colon tumors, approaching statistical significance (P = 0.06) and suggesting that rectal cancers harbor oncogenic pathways that are different from colon cancers [43]. This evidence concerns the gene KRAS and rectal cancer.